Dulaglutide

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Dulaglutide and local guidelines before prescribing.

GLP-1 receptor agonist

Mechanism

Once-weekly GLP-1 receptor agonist.

Uses

Type 2 diabetes with cardiovascular benefit.

Dosing

Side effects

Nausea, diarrhoea, pancreatitis, injection-site reaction.

Interactions

Insulin and sulfonylureas hypoglycaemia.

Contraindications and cautions

Pancreatitis history

Monitoring

HbA1c, weight

Pregnancy and breastfeeding

Avoid

Renal and hepatic impairment

No adjustment

Overdose and reversal

Supportive

Special advice

Weekly injection; titrate slowly.

More from the textbook: uses, cautions and other points
Where it is discussed in the book